Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 10:01 AM ET

Date/Time Source News Release
06/05/2025 07:00 AM EDT GlobeNewswire Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
05/14/2025 07:32 AM EDT GlobeNewswire Emergent BioSolutions to Participate in Upcoming Investor Conferences
05/07/2025 04:05 PM EDT GlobeNewswire Emergent BioSolutions Reports First Quarter 2025 Financial Results
05/01/2025 05:07 PM EDT GlobeNewswire Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
04/22/2025 08:00 AM EDT GlobeNewswire Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
03/31/2025 08:00 AM EDT GlobeNewswire Emergent BioSolutions Announces Stock Repurchase Program
03/20/2025 04:30 PM EDT GlobeNewswire Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
03/20/2025 08:06 AM EDT GlobeNewswire Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
03/19/2025 04:30 PM EDT GlobeNewswire Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
03/18/2025 08:00 AM EDT GlobeNewswire Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
Page